Methods:
454 UBC patients were sequenced using next generation sequencing assay (MSK−IMPACT). 264 patients with chemotherapy naïve primary tumors were included. A total of 123 patients had non-muscle invasive bladder cancer [NMIBC], 112 patients had muscle invasive bladder cancer [MIBC] and 29 were metastatic patients.
Results:
Patients whose primary tumors harbored:
- TP53
- RB1
- TP53/MDM2,
- cell cycle pathway alterations
More frequently presented with advanced disease, whereas those with tumors containing:
- FGFR3
- RTK/RAS/RAF pathway alterations
Conclusions:
In summary, TP53, RB1 and FGFR3 alterations as well as TP53/MDM2, cell cycle and RTK/RAS/RAF pathway alterations showed an association with tumor stage and patient outcomes. MIBC with DDR alterations had higher pathological downstaging as well as better overall survival compared to MIBC without DDR alterations after platinum−based neoadjuvant chemotherapy. In absence of neoadjuvant chemotherapy, MIBC with and without DDR alterations have similar patient outcomes.
Speaker: Sumit Isharwal, MSKCC, New-York, USA
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, Twitter:@GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA